MARKET

INCY

INCY

Incyte Corp
NASDAQ
123.20
-1.62
-1.30%
After Hours: 123.01 -0.19 -0.16% 19:30 09/29 EDT
OPEN
123.67
PREV CLOSE
124.82
HIGH
125.47
LOW
121.89
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
132.60
52 WEEK LOW
82.52
MARKET CAP
24.97B
P/E (TTM)
15.70
1D
5D
1M
3M
1Y
5Y
1D
Incyte’s KRAS G12D Lead Supports Undervalued Upside as Kapoor Reiterates Buy and Maintains $152 Price Target
TipRanks · 23h ago
Incyte (INCY), What Is Behind The Fresh Attention?
Simply Wall St · 1d ago
Incyte management to meet with Oppenheimer
TipRanks · 1d ago
Incyte Is Maintained at Neutral by JP Morgan
Dow Jones · 1d ago
Incyte Price Target Raised to $123.00/Share From $120.00 by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123
Benzinga · 1d ago
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
Benzinga · 1d ago
Incyte price target raised to $123 from $120 at JPMorgan
TipRanks · 1d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.